Does Blue Cross Blue Shield Cover Forteo? A Woman's Complete Guide to Teriparatide Insurance Coverage

What Forteo Is and Why Women Are the Primary Patients

Forteo is a daily self-injected parathyroid hormone analog that builds new bone rather than simply slowing bone loss. That distinction matters clinically. Most women prescribed Forteo are postmenopausal, have already sustained a fragility fracture, or have a T-score below -2.5 on DEXA scan with additional high-risk features.

Osteoporosis affects approximately 10.2 million women in the United States, compared to 2 million men. The sex difference traces directly to the dramatic estrogen decline at menopause, which accelerates osteoclast activity and tips the bone-remodeling balance toward net loss. Forteo works by activating the PTH1 receptor intermittently, stimulating osteoblast function and net bone formation, a mechanism that is equally effective in women at any postmenopausal age.

Who Gets Prescribed Forteo

Prescriptions cluster around several clinical scenarios that are nearly all female-dominant:

• Postmenopausal women with a T-score <-3.0 or a previous hip or vertebral fracture
• Women with glucocorticoid-induced osteoporosis (a BCBS coverage criterion in many plans)
• Women in whom bisphosphonates caused severe gastrointestinal side effects or osteonecrosis of the jaw
• Premenopausal women with idiopathic osteoporosis, though this group is far less common and evidence is more limited

The Anabolic Bone-Building Advantage

Bisphosphonates reduce fracture risk by 40-70% in high-risk postmenopausal women. Teriparatide in the Fracture Prevention Trial reduced new vertebral fractures by 65% and non-vertebral fractures by 53% over 21 months, making it one of the most effective anabolic agents available. That data was gathered primarily in postmenopausal women aged 42 to 86, so the evidence base is genuinely female-grounded.

How BCBS Plans Classify Forteo on Their Formularies

Blue Cross Blue Shield is a federation of 35 independent regional plans, not a single national insurer. That structure is the single biggest source of confusion for women trying to predict their coverage.

National vs. Regional Plan Variation

Each BCBS affiliate maintains its own formulary. Anthem Blue Cross in California may place Forteo on a different tier than BCBS of North Carolina or BCBS of Michigan. What is consistent across nearly all plans is that Forteo lands on the specialty formulary tier, which carries the highest member cost-sharing.

Typical tier designations you will see:

| BCBS Plan Type | Typical Forteo Tier | Estimated Monthly Copay Range | |---|---|---| | Employer-sponsored (large group) | Specialty Tier 4 | $100 to $400 | | Federal Employee Program (FEP) | Specialty Tier 4 | $80 to $300 | | Individual ACA Marketplace | Specialty Tier 5 | $200 to $600 | | Medicare Advantage | Tier 4 or 5 | Varies widely by plan | | Medicaid managed care | Prior auth; may be $0 | State-dependent |

These are estimates. Your actual cost depends on your specific plan year, whether you have met your deductible, and whether you are in an in-network or out-of-network pharmacy.

How to Look Up Your Specific Plan's Coverage in 10 Minutes

1. Log in to your BCBS member portal and manage to "Drug Coverage" or "Formulary."
2. Search "teriparatide" (the generic name) or "Forteo."
3. Note the tier number and any PA (prior authorization) or ST (step therapy) flags.
4. Call the member services number on your insurance card and ask: "What are the prior authorization criteria for Forteo, and does my plan require step therapy with a bisphosphonate first?"

Record the representative's name, date, and reference number for every call. You will need this documentation if you appeal.

Prior Authorization: What BCBS Actually Requires

Prior authorization for Forteo exists because the drug costs approximately $26,000 to $29,000 per year at list price without assistance, and because clinical guidelines genuinely recommend bisphosphonates as first-line therapy for most women.

Typical PA Criteria Across BCBS Plans

Most BCBS plans approve Forteo when your physician documents at least one of these:

• A diagnosis of osteoporosis confirmed by DEXA with T-score <-2.5 or a fragility fracture
• Failure of, contraindication to, or intolerance of oral bisphosphonate therapy (alendronate, risedronate) for at least 6 months
• Glucocorticoid use equivalent to 5 mg prednisone daily for 3 months or longer
• Severe osteoporosis (T-score <-3.5 or multiple vertebral fractures) that your physician documents as warranting anabolic rather than antiresorptive first-line therapy

What "Bisphosphonate Failure" Means for the PA Form

BCBS reviewers look for one or more of these on the PA form:

• Documented intolerance (esophageal ulcer, severe GERD, musculoskeletal pain leading to discontinuation)
• Non-response: fracture occurring or significant bone loss on DEXA despite 12 months of consistent bisphosphonate use
• Contraindication such as renal insufficiency with eGFR <35 mL/min/1.73 m² (a Kidney Disease: Improving Global Outcomes threshold frequently cited in PA criteria)

Your prescribing physician's office typically submits the PA. Ask specifically whether they have experience with BCBS Forteo PA paperwork, because incomplete submissions are the most common cause of first-round denials.

Typical PA Decision Timeline

Most BCBS plans respond within 3 to 15 business days for standard reviews. Urgent reviews, available when a physician certifies clinical urgency, must receive a decision within 72 hours under federal parity rules. If you are denied, you have the right to an internal appeal and, after exhausting internal appeals, an external independent medical review under the ACA.

Step Therapy Requirements and How to Bypass Them

Step therapy means your insurer requires you to try a cheaper drug first. For Forteo, step therapy almost always means a bisphosphonate trial, typically alendronate 70 mg weekly or risedronate 35 mg weekly for 6 to 12 months.

When Step Therapy Can Be Skipped

Your physician can submit a step-therapy exception request when:

• You had a severe adverse reaction to bisphosphonates (documented in the medical record)
• Your fracture risk is so high that waiting 6 months for anabolic therapy is clinically unreasonable
• You are already taking glucocorticoids at a dose that qualifies for direct Forteo approval
• You have renal impairment precluding bisphosphonate use

Many states have passed step-therapy reform laws that limit when insurers can impose step therapy and require faster exception reviews. States with enacted protections as of 2024 include New York, Texas, Florida, Virginia, and over 30 others. If your BCBS plan is a fully-insured state plan (as opposed to a self-funded employer plan under ERISA), your state law protections apply.

The 24-Month Treatment Limit and What Happens After

The FDA caps Forteo use at 24 months cumulative over a lifetime because animal studies at high supraphyraphysiologic doses showed osteosarcoma risk, though no increased osteosarcoma rate has been observed in humans at the therapeutic 20 mcg/day dose after two decades of post-marketing surveillance.

BCBS plans enforce this FDA cap. Most plans authorize Forteo in 6-month increments and require documentation of ongoing treatment response (typically a follow-up DEXA or clinical assessment) to renew each period.

Transition to Antiresorptive Therapy After Forteo

Stopping Forteo without transitioning immediately to an antiresorptive drug causes rapid bone loss. The Endocrine Society's clinical practice guideline recommends transitioning directly to a bisphosphonate or denosumab (Prolia) after completing the 24-month Forteo course. BCBS coverage for the follow-on drug should be arranged before you dispense the final Forteo auto-injector pen.

Life-Stage Considerations: Who This Medication Is Right For

Postmenopausal Women (the Primary Forteo Population)

Postmenopausal women account for the vast majority of Forteo prescriptions. Estrogen withdrawal accelerates bone turnover, and by age 70, a woman may have lost 30% of her peak bone mass. Forteo is particularly well-suited for postmenopausal women with severe vertebral osteoporosis who need rapid fracture risk reduction before fracture cascade begins.

BCBS coverage criteria for this group are generally the most straightforward: document the T-score, document bisphosphonate failure or intolerance, and submit.

Perimenopausal Women

Perimenopause brings irregular estrogen fluctuations that begin bone loss years before the last menstrual period. Most perimenopausal women with low bone density are not yet candidates for Forteo; bisphosphonates or hormone therapy remain first line. Forteo coverage for a perimenopausal woman would require exceptional clinical circumstances, and BCBS reviewers may push back without detailed documentation.

Women with PCOS

Women with polycystic ovary syndrome can have reduced bone density related to menstrual irregularity and hypoestrogenism, but PCOS is not a recognized BCBS criterion for Forteo approval. If a woman with PCOS has documented osteoporosis meeting the standard T-score and fracture criteria, the PA process is the same as for any other premenopausal woman with idiopathic osteoporosis.

Premenopausal Women with Idiopathic Osteoporosis

This is the group where data is thinnest. The Endocrine Society notes that evidence for teriparatide in premenopausal women is limited to small observational studies. BCBS plans may require specialist (endocrinologist or rheumatologist) documentation for coverage in this population. Some plans explicitly list "postmenopausal" as a required diagnosis in their PA criteria, which would require an appeal or clinical exception letter for a premenopausal woman.

Women with Glucocorticoid-Induced Osteoporosis

This group spans all reproductive life stages. Women taking chronic glucocorticoids for autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) are at high risk for rapid bone loss regardless of age. The American College of Rheumatology guideline for glucocorticoid-induced osteoporosis supports anabolic therapy as a treatment option, and most BCBS plans follow this guidance in their PA criteria.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting Forteo

Forteo is contraindicated during pregnancy. This section is not optional reading if you are of reproductive age.

Pregnancy

Teriparatide carries FDA Pregnancy Category C status. Animal reproductive studies at high doses showed skeletal effects in offspring. There are no adequate, well-controlled studies of teriparatide in pregnant women. Because the drug crosses the placenta in animal models, prescribers generally advise women of reproductive potential to use reliable contraception during the full 24-month treatment course.

If you discover you are pregnant while on Forteo, stop the injection and contact your prescriber immediately. Report exposure to the National Pregnancy Registry for Osteoporosis Medications if one is available for your region.

Lactation

Teriparatide transfer into human breast milk has not been adequately studied. Because the potential risk to a nursing infant is unknown and cannot be excluded, prescribing guidelines advise against using Forteo while breastfeeding. Postpartum women with severe osteoporosis who need treatment should discuss timing with their prescriber: weaning first, then initiating Forteo, is the standard approach.

Contraception Requirement

No published FDA labeling requires formal contraception documentation as a dispensing condition for Forteo (unlike, for example, the iPLEDGE program for isotretinoin). However, prescribers routinely counsel women of reproductive potential to use effective contraception during treatment given the lack of human safety data in pregnancy. Your BCBS PA form will not ask about contraception status, but your prescriber should document this conversation in your medical record.

Reducing Your Out-of-Pocket Cost: Patient Assistance and Appeals

Lilly Cares Foundation

Eli Lilly manufactures Forteo and operates the Lilly Cares Foundation patient assistance program. Patients who meet income eligibility (generally household income at or below 400% of the Federal Poverty Level) may receive Forteo at no cost. Patients with commercial insurance who have high cost-sharing may qualify for a co-pay card reducing monthly cost to as low as $0.

Apply through the Lilly Cares Foundation directly, or ask your prescriber's office to initiate enrollment. Processing typically takes 2 to 4 weeks.

Appealing a BCBS Denial

If BCBS denies your PA, you have the right to:

1. An internal first-level appeal (submit within 180 days of denial)
2. A second-level internal appeal if the first is denied
3. An external independent review (required under ACA for non-grandfathered plans)

Your physician should submit a letter of medical necessity with the appeal, citing specific clinical guidelines. A direct quotation from a guideline carries weight. The Endocrine Society's 2019 osteoporosis guideline states: "For patients with very high fracture risk, treatment with an anabolic agent (teriparatide, abaloparatide, or romosozumab) is preferred over antiresorptive therapy." Including this statement in an appeal letter, alongside your fracture history or T-score data, significantly strengthens the case for direct Forteo authorization without step therapy.

Medicare and Forteo

Forteo falls under Medicare Part D (prescription drug benefit). Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap that takes full effect in 2025, Medicare Part D beneficiaries pay a maximum of $2,000 per year for all covered Part D drugs including specialty drugs like Forteo. This is a major change from prior years when specialty drug costs could exceed $5,000 per year under Part D.

Comparing Forteo to Alternatives Your BCBS Plan May Prefer

BCBS plans sometimes steer patients toward alternatives because of formulary positioning. Here is how the main anabolic and high-efficacy antiresorptive options compare from a coverage standpoint:

| Drug | Mechanism | Typical BCBS Tier | 24-Month Limit | Injection Frequency | Pregnancy Status | |---|---|---|---|---|---| | Forteo (teriparatide) | Anabolic (PTH analog) | Specialty 4-5 | Yes (lifetime) | Daily | Contraindicated | | Tymlos (abaloparatide) | Anabolic (PTHrP analog) | Specialty 4-5 | Yes (18 months) | Daily | Contraindicated | | Evenity (romosozumab) | Anabolic/antiresorptive | Specialty 4-5 | Yes (12 months) | Monthly injection | Contraindicated | | Prolia (denosumab) | Antiresorptive | Specialty 3-4 | No | Every 6 months injection | Contraindicated | | Alendronate (generic) | Antiresorptive | Tier 1-2 | No | Weekly oral | Generally avoided |

If your BCBS plan denies Forteo specifically, Tymlos (abaloparatide) may be an alternative anabolic agent with a similar PA pathway. Abaloparatide reduced vertebral fracture risk by 86% versus placebo in the ACTIVE trial, with a population that was almost entirely postmenopausal women.

What Your Prescriber Needs to Do for a Successful PA Submission

A clean prior authorization submission for Forteo typically requires your prescriber to document:

• Your diagnosis code (M81.0 for postmenopausal osteoporosis, M80.0 for age-related osteoporosis with fracture, or M81.6 for glucocorticoid-induced osteoporosis)
• DEXA T-score within the past 24 months (most BCBS plans accept up to 2 years old)
• Fracture history if applicable, with imaging reports
• Name, dose, duration, and reason for bisphosphonate discontinuation if step therapy applies
• A brief clinical narrative explaining why anabolic therapy is appropriate now

The narrative is where many PA submissions fall short. A single sentence ("Patient has osteoporosis and needs Forteo") is not sufficient. Two to three sentences citing BCBS's own osteoporosis clinical criteria document, your specific T-score, and your fracture risk score (FRAX) will meaningfully improve approval odds.

Ask your prescriber's office whether they use a specialty pharmacy PA support service. Lilly's own patient support program, Lilly Cares/Lilly Answers, can help coordinate the PA submission at no charge.

Monitoring While on Forteo: What BCBS May Require for Renewals

BCBS plans that authorize Forteo in 6-month increments typically require evidence of treatment monitoring at renewal. Standard monitoring for teriparatide includes:

• Serum calcium (hypercalcemia risk, though uncommon at 20 mcg/day)
• Serum creatinine and eGFR (baseline and periodic)
• DEXA scan at 12 months to document treatment response (though bone density changes at 12 months are modest; the real benefit is fracture reduction, not just T-score change)
• Assessment for orthostatic hypotension, a recognized side effect particularly in older women initiating therapy

Women using Forteo have a reported 11% incidence of mild hypercalcemia on spot urine or serum testing, usually transient and not clinically significant at recommended dosing. Calcium supplementation above 1,500 mg/day during Forteo treatment may increase this risk and is generally not recommended.